US FDA's Yim Hopes To See European-Like Robustness For US Biosimilars Market In 10 Years
Executive Summary
In an exclusive interview with the Pink Sheet, the now-permanent OTBB director Sarah Yim discussed her expectations for the future of the US biosimilars market, her learning experience as acting director and upcoming challenges for her office.
You may also be interested in...
Amgen Sees A Vibrant US Biosimilars Market
Biosimilar executives Leah Christl and Chad Pettit see reasons for optimism in the US market as new launches and sales begin to add up. Amgen’s portfolio is annualizing at $1bn as of the fourth quarter.
Amgen Sees A Vibrant Biosimilars Market As Its Business Pushes Into Blockbuster Territory
Biosimilar executives Leah Christl and Chad Pettit see reasons for optimism in the US market as new launches and sales begin to add up. Amgen’s portfolio is annualizing at $1bn as of the fourth quarter.
FDA Warns Over Denigrating Biosimilars
The guidance states that promotion creating an impression that differences are clinically meaningful when the US FDA has said they are not could be judged misleading.